Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hoogwerf, Byron J.
Lincoff, A. Michael
Funding for this research was provided by:
Eli Lilly and Company